REFERENCES:

Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352(9132):930-42. Abstract

Buban GM et al. Influences on oncologists’ adoption of new agents in adjuvant chemotherapy of breast cancer. J Clin Oncol 2001;19:954-9. Abstract

Cardoso F et al. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node-positive breast cancer: Results of a feasibility study. Anticancer Res 2001;21:789-95. Abstract

Diab SG et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999;17:1442-8. Abstract

Colleoni M et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 2000;18:584-90. Abstract

Fisher B et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-42. Abstract

Fisher B et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001;93:112-20. Abstract

Hortobagyi GN. Progress in systemic chemotherapy of primary breast cancer: An overview. J Natl Cancer Inst Monogr 2001;30:;72-79. Abstract

Jansen SJ et al. Patients’ preferences for adjuvant chemotherapy in early-stage breast cancer: Is treatment worthwhile? Br J Cancer 2001;84(12):1577-1585. Abstract

Joly F et al. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer 2000;83(5):577-582. Abstract

Levine MN et al. Randomized trial of intensive clophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16(8):2651-8. Abstract

Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972- 9. Abstract

Mamounas EP, Sledge GW Jr. Combined anthracycline-taxane regimens in the adjuvant setting. Semin Oncol 2001;28(4 Suppl 12):24-31. Abstract

Michaud LB et al. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000;23:401-28. Abstract

Morrow M, Krontiras H. Who should not receive chemotherapy? Data from American databases and trials. Cancer Inst Monogr 2001;30:;109-113. Abstract

Nabholtz JM et al. Chemotherapy of breast cancer: Are the taxanes going to change the natural history of breast cancer? Expert Opin Pharmacother 2000;1:187-206. Abstract

Nabholtz JM et al. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol 2000;27:11-8. Abstract

Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001;6 Suppl 3:30-5. Abstract

Piccart MJ et al. Taxanes in the adjuvant treatment of breast cancer: Why not yet? J Natl Cancer Inst Monogr 2001;30:;88-95. Abstract

Piccart MJ et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:3103-10. Abstract

Ravdin PM et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91. Abstract

Mayo Clinic’s webtool for determining adjuvant breast cancer treatment benefits. Web link

Back | Top of Page